Cenexi aims to contribute to consolidating a powerful French health industry.
CDMO, a strategic activity
The industrial reconquest led by the public authorities, combined with the imperative to relocate drug production to France, have promoted pharmaceutical manufacturing and, therefore, CDMO business to the rank of strategic activity at the heart of health safety and sovereignty issues.
TODAY, NEARLY 85% OF FRENCH BIOTECHS USE SUBCONTRACTORS FOR THEIR R&D AND/OR DRUG AND BIOPHARMACEUTICALS PRODUCTION
(Source : France Biotech, 405 sociétés, décembre 2020).
This trend is expected to accelerate by 2030 due to the development of innovative biopharmaceuticals (monoclonal antibodies, cell and gene therapies) and increasingly personalized medicine.
The entire ecosystem and the authorities therefore agree on the need and strategic importance of facilitating the establishment and operations of CMOs and CDMOs on the French market to secure the supply chain.
As a leading CDMO specializing in sterile products, simultaneously developing partnerships with innovative biotechs and the manufacture of biological products, Cenexi aims to contribute to consolidating a powerful French health industry, whether by boosting drug production in France or by making the country a land of innovation serving patients.
All of Cenexi’s teams are focused on this goal, with the final ambition of boosting the production of medicines in France and making the country a land of innovation and industry in the health sector for the benefit of patients.